The effect of (R)-HA966 or ACEA 1021 on dexfenfluramine or (5)-MDMA-induced changes in temperature, activity, and neurotoxicity

Pharmacology Biochemistry and Behavior

Volumn 68, Issue 3, 2001, Pages 565-574

  Russell, B R ^a   Laverty, R ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

(R) HA 966; ACEA 1021; Dexfenfluramine; MDMA; Neurotoxicity; Nmda antagonists; Rats; Temperature

Indexed keywords

3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; DEXFENFLURAMINE; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL TISSUE; ARTICLE; BINDING SITE; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFECT; DRUG SPECIFICITY; HYPERTHERMIA; HYPOTHERMIA; LOCOMOTION; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; RAT; RECEPTOR DENSITY;

ANIMALS; AUTORADIOGRAPHY; BODY TEMPERATURE; BRAIN CHEMISTRY; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DEXFENFLURAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MOTOR ACTIVITY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NERVE TISSUE PROTEINS; NEUROTOXICITY SYNDROMES; PYRROLIDINONES; QUINOXALINES; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN; SEROTONIN AGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM; TELEMETRY;

EID: 0035006658     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-3057(01)00454-3     Document Type: Article

References (67)

1. Appel NM, Mitchell WM, Contrera JF, De Souza EB. Effects of high-dose fenfluramine treatment on monoamine uptake sites in rat brain: assessment using quantitative autoradiography. Synapse 1990;6:33-44.
2. Aulakh CS, Hill JL, Wozniak KM, Murphy DL. Fenfluramine-induced suppression of food intake and locomotor activity is differentially altered by the selective type A monoamine oxidase inhibitor clorgyline. Psychopharmacology (Berlin) 1988;95:313-7.
3. 3H]paroxetine-labeled serotonin uptake sites. J Pharmacol Exp Ther 1987;242:911-6.
4. Bowyer JF, Davies DL, Schmued L, Broening HW, Newport GD, Slikker W, Holson RR. Further studies of the role of hyperthermia in methamphetamine neurotoxicity. J Pharmacol Exp Ther 1994;268:1571-80.
5. Broening HW, Bowyer JF, Slikker W. Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (±)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J Pharmacol Exp Ther 1995; 275:325-33.
6. Brownsill R, Wallace D, Taylor A, Campbell B. Study of human urinary metabolism of fenfluramine using gas chromatography-mass spectrometry. J Chromatogr 1991;562:267-77.
7. Callaway CW, Geyer MA. Stimulant effects of 3,4-methylenedioxymethamphetamine in the nucleus accumbens of rat. Eur J Pharmacol 1992;214:45-51.
8. Callaway CW, Wing LL, Nichols DE, Geyer MA. Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release. Psychopharmacology (Berlin) 1993;111:169-78.
9. Clark WG, Lipton JM. Changes in body temperature after administration of adrenergic and serotonergic agents and related drugs including antidepressants: II. Neurosci Biobehav Rev 1986;10:153-220.
10. Clement JG, Mills P, Brockway B. Use of telemetry to record body temperature and activity in mice. J Pharmacol Methods 1989;21:129-40.
11. Colado MI, Green AR. A study of the mechanism of MDMA ('ecstasy')induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds. Br J Pharmacol 1994; 111:131-6.
12. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS. Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 1987;241:338-45.
13. Cox B. Pharmacologic control of temperature regulation. Annu Rev Pharmacol Toxicol 1977;17:341-53.
14. De Souza EB, Battaglia G. Effects of MDMA and MDA on brain serotonin neurons: evidence from neurochemical and autoradiographic studies. NIDA Res Monogr 1989;94:196-222.
15. 3H-paroxetinelabeled serotonin uptake sites in rat brain. Synapse 1987;l:488-96.
16. Dilsaver SC, Overstreet DH, Peck JA. Measurement of temperature in the rat by rectal probe and telemetry yields compatible results. Pharmacol, Biochem Behav 1992;42:549-52.
17. Dragunow M, Logan B, Laverty R. 3,4-Methylenedioxymethamphetamine induces Fos-like proteins in rat basal ganglia: reversal with MK 801. Eur J Pharmacol 1991;206:255-8.
18. Even P, Nicolaidis S. Dextrofenfluramine increases energy cost of muscular effort. Pharmacol, Biochem Behav 1986;24:647-55.
19. Fallon JK, Kicman AT, Henry JA, Milligan PJ, Cowan DA, Hutt AJ. Stereospecific analysis and enantiomeric disposition of 3,4-methylenedioxymethamphetamine (Ecstasy) in humans. Clin Chem 1999;45: 1058-69.
20. Farfel GM, Seiden LS. Role of hypothermia in the mechanism of protection against serotonergic toxicity: I. Experiments using 3,4-methylenedioxymethamphetamine, dizocilpine, CGS 19755 and NBQX. J Pharmacol Exp Ther 1995a;272:860-7.
21. Farfel GM, Seiden LS. Role of hypothermia in the mechanism of protection against serotonergic toxicity: II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J Pharmacol Exp Ther 1995b;272:868-75.
22. Frith CH, Chang LW, Lattin DL, Walls RC, Hamm J, Doblin R. Toxicity of methylenedioxymethamphetamine (MDMA) in the dog and the rat. Fundam Appl Toxicol 1987;9:110-9.
23. Glennon RA, Little PJ, Rosecrans JA, Yousif M. The effect of MDMA ("Ecstasy") and its optical isomers on schedule-controlled responding in mice. Pharmacol, Biochem Behav 1987;26:425-6.
24. Gordon CJ, Watkinson WP, O'Callaghan JP, Miller DB. Effects of 3,4methylenedioxymethamphetamine on autonomie thermoregulatory responses of the rat. Pharmacol, Biochem Behav 1991;38:339-44.
25. Guerra MJ, Liste I, Labandeira-Garcia JL. Interaction between the serotonergic, dopaminergic, and glutamatergic systems in fenfluramine-induced Fos expression in striatal neurons. Synapse 1998;28:71-82.
26. Hanson GR, Singh N, Bush L, Gibb JW. Response of extrapyramidal and limbic neuropeptides to fenfluramine administration: comparison with methamphetamine. J Pharmacol Exp Ther 1991;259:1197-202.
27. Hardman HF, Haavik CO, Seevers MH. Relationship of the structure of mescaline and seven analogs to toxicity and behavior in five species of laboratory animals. Toxicol Appl Pharmacol 1973;25:299-309.
28. Hatzidimitriou G, McCann UD, Ricaurte GA. Altered serotonin innervation patterns in the forebrain of monkeys treated with (±)3,4-methylenedioxymethamphetamine seven years previously: factors influencing abnormal recovery. J Neurosci 1999;19:5096-107.
29. Henry JA, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Forsling M. Lowdose MDMA ("Ecstasy") induces vasopressin secretion. Lancet 1998;351:1784.
30. 3H]imipramine localization and relationship to serotonin transporter. J Pharmacol Exp Ther 1990;252:410-8.
31. Johnson MP, Nichols DE. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine. Pharmacol, Biochem Behav 1990;36:105-9.
32. 3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 1986;132:269-76.
33. Kanthasamy AG, Kanthasamy A, Matsumoto RR, Vu TQ, Truong DD. Neuroprotective effects of the strychnine-insensitive glycine site NMDA antagonist (A)-HA-966 in an experimental model of Parkinson's disease. Brain Res 1997;759:l-8.
34. Kleven MS, Schuster CR, Seiden LS. Effect of depletion of brain serotonin by repeated fenfluramine on neurochemical and anorectic effects of acute fenfluramine. J Pharmacol Exp Ther 1988;246:822-8.
35. Layer RT, Bland LR, Skolnick P. MK-801, but not drugs acting at strychnine-insensitive glycine receptors, attenuate methamphetamine nigrostriatal toxicity. Brain Res 1993;625:38-44.
36. Lenton S, Boys A, Norcross K. Raves, drugs and experience: drug use by a sample of people who attend raves in Western Australia. Addiction 1997;92:1327-37.
37. Logan BJ, Laverty R, Sanderson WD, Yee YB. Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity. Eur J Pharmacol 1988; 152:227-34.
38. Malberg JE, Seiden LS. Administration of fenfluramine at different ambient temperatures produces different core temperature and 5-HT neurotoxicity profiles. Brain Res 1997;765:101-7.
39. Malberg JE, Seiden LS. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J Neurosci 1998;18:5086-94.
40. Malberg JE, Sabol KE, Seiden LS. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 1996;278:258-67.
41. Matsumoto RR, Brackett RL, Kanthasamy AG. Novel NMDA/glycine site antagonists attenuate cocaine-induced behavioral toxicity. Eur J Pharmacol 1997;338:233-42.
42. McCann U, Hatzidimitriou G, Ridenour A, Fischer C, Yuan J, Katz J, Ricaurte G. Dexfenfluramine and serotonin neurotoxicity: further preclinical evidence that clinical caution is indicated. J Pharmacol Exp Ther 1994;269:792-8.
43. McCann UD, Szabo Z, Scheffel U, Dannais RF, Ricaurte GA. Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings. Lancet 1998;352:1433-7.
44. Miller DB, O'Callaghan JP. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse. J Pharmacol Exp Ther 1994;270: 752-60.
45. Miller DB, O'Callaghan JP. The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine. Mol Neurobiol 1995;! 1: 177-92.
46. Morrow BA, Taylor JR, Roth RH. A-(+)-HA-966, an antagonist for the glycine/NMDA receptor, prevents locomotor sensitization to repeated cocaine exposures. Brain Res 1995;673:165-9.
47. Nash JF, Yamamoto BK. Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res 1992;581:237-43.
48. Nichols DE, Hoffman AJ, Oberlender RA, Jacob PD, Shulgin AT. Derivatives of l-(l,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J Med Chem 1986;29:2009-15.
49. Palkovits M, Brownstein MJ. Maps and guide to microdissection of the rat brain Elsevier, New York 1988.
50. Palkovits M, Zaborszky L, Brownstein MJ, Fekete MI, Herman JP, Kanyicska B. Distribution of norepinephrine and dopamine in cerebral cortical areas of the rat. Brain Res Bull 1979;4:593-601.
51. Papp M, Moryl E, Maccecchini ML. Differential effects of agents acting at various sites of the NMDA receptor complex in a place preference conditioning model. Eur J Pharmacol 1996;317:191-6.
52. Paxinos G, Watson C. The rat brain in stereotoxic coordinates Academic London. 1997.
53. Ricaurte GA, DeLanney LE, Irwin I, Längsten JW. Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administration. Brain Res 1988;446:165-8.
54. Rocher C, Jacquot C, Gardier AM. Simultaneous effects of local dexfenfluramine application on extracellular glutamate and serotonin levels in rat frontal cortex: a reverse microdialysis study. Neuropharmacology 1999;38:513-23.
55. Sabol KE, Richards JB, Seiden LS. The NMDA receptor antagonist MK801 does not protect against serotonin depletions caused by high doses of DL-fenfluramine. Brain Res 1992;582:129-33.
56. Scheffel U, Ricaurte GA. Paroxetine as an in vivo indicator of 3,4-methylenedioxymethamphetamine neurotoxicity: a presynaptic serotonergic positron emission tomography ligand? Brain Res 1990;527:89-95.
57. Schmidt CJ. Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and Nethyl analogs. Eur J Pharmacol 1987;136:81-8.
58. Schmidt CJ, Kehne JH. Neurotoxicity of MDMA: neurochemical effects. Ann NY Acad Sei 1990;600:665-80 (Discussion 680-1).
59. Schmidt CJ, Levin JA, Lovenberg W. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain. Biochem Pharmacol 1987;36:747-55.
60. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('Ecstasy') users. Br J Psychiatry 1999;175:63-9.
61. Shankaran M, Gudelsky GA. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin. Pharmacol, Biochem Behav 1998;61:361-6.
62. Slikker W, Ali SF, Scallet AC, Frith CH, Newport GD, Bailey JR. Neurochemical and neurohistological alterations in the rat and monkey produced by orally administered methylenedioxymethamphetamine (MDMA). Toxicol Appl Pharmacol 1988;94:448-57.
63. Stewart CW, Bowyer JF, Slikker W. Elevated environmental temperatures can induce hyperthermia during D-fenfluramine exposure and enhance 5-hydroxytryptamine (5-HT) depletion in the brain. J Pharmacol Exp Ther 1997;283:1144-50.
64. Tessel RE, Woods JH, Counsell RE, Lu M. Structure-activity relationships between meta-substituted A'-ethylamphetamines and locomotor activity in mice. J Pharmacol Exp Ther 1975;192:310-8.
65. Warner DS, Martin H, Ludwig P, McAllister A, Keana JF, Weber E. In vivo models of cerebral ischemia: effects of parenterally administered NMDA receptor glycine site antagonists. J Cereb Blood Flow Metab 1995;15:188-96.
66. Webb E, Ashton CH, Kelly P, Kamali F. Alcohol and drug use in UK university students. Lancet 1996;348:922-5.
67. Yehuda S, Wurtman RJ. The effects of D-amphetamine and related drugs on colonie temperatures of rats kept at various ambient temperatures. Life Sei 1972;11:851-9 (I).